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Figure S75. Cell death analysis of NCI-H460 cells untreated and treated with 50 μM curcumin and compounds 1 and 14 for 72h. The 
samples were analyzed for green fluorescence (Annexin-V-FITC, FL1-H) and red fluorescence (Propidium Iodide, FL2-H) by flow-
cytometry. The assay distinguishes viable cells (AV-PI-), apoptotic cells (AV+PI-), late apoptotic and necrotic cells (AV+PI+) and 
secondary necrotic or dead cells (AV-PI+). 
 
 
 
 
 
Figure S76. Doxorubicin accumulation in multi-drug resistant cells (NCI-H460/R) and multi-drug resistant cells treated with 
diarylheptanoids (alnuside A (3) and methylhirsutanonol (6)) and a positive control (curcumin). Doxorubicin accumulation was 
increased in all treated samples compared to untreated control (NCI-H460/R). 
 
 
 
Figure S77. Overlapped HPLC chromatograms of D-glucose standard and hydrolyzed compounds 14, 15, and 16. 
 
 
 
Figure S78. Overlapped HPLC chromatograms of D-glucose standard and hydrolyzed compounds 20, 21, and 22. 
 {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12} {13} {14} {15} {16} {17} {18} {19} {20} {21} {22} {23} {24} 
1        {1}   * / / *** / ** / / *** *** *** *** / / *** / / *** *** ** *** *** *** 
2        {2} *   ** / *** ** *** *** / *** *** *** *** / *** *** *** * *** *** *** *** *** *** 
3        {3} / **   * *** / / / * *** *** *** *** / / *** / / *** *** * *** *** *** 
4        {4} / / *   *** * *** *** / *** *** *** *** / *** *** *** / *** *** *** *** *** *** 
5        {5} *** *** *** ***   *** *** *** *** *** *** *** / *** *** / *** *** / * ** *** / / 
6        {6} / ** / * ***   * / / *** *** *** *** / / *** / / *** *** ** *** *** *** 
7        {7} ** *** / *** *** *   / *** *** *** *** ** *** / ** / ** / / / *** ** / 
8        {8} / *** / *** *** / /   *** *** *** *** *** * / *** / / *** / / *** *** * 
9        {9} / / * / *** / *** ***   *** *** *** *** / *** *** *** / *** *** *** *** *** *** 
10     {10} *** *** *** *** *** *** *** *** ***   / / *** *** *** *** *** *** *** *** *** / *** *** 
11     {11} *** *** *** *** *** *** *** *** *** /   ** *** *** *** *** *** *** *** *** *** * *** *** 
12     {12} *** *** *** *** *** *** *** *** *** / **   *** *** *** *** *** *** *** *** *** / *** *** 
13     {13} *** *** *** *** / *** ** *** *** *** *** ***   *** *** / *** *** / / * *** / / 
14     {14} / / / / *** / *** * / *** *** *** ***   / *** ** / *** *** *** *** *** *** 
15     {15} / *** / *** *** / / / *** *** *** *** *** /   *** / / *** * / *** *** ** 
16     {16} *** *** *** *** / *** ** *** *** *** *** *** / *** ***   *** *** / / ** *** / / 
17     {17} / *** / *** *** / / / *** *** *** *** *** ** / ***   / *** / / *** *** / 
18     {18} / * / / *** / ** / / *** *** *** *** / / *** /   *** *** ** *** *** *** 
Statistical significance: 
* p< 0.05, ** p < 0.01, *** p< 0.001, / no significance 
 
Table S79. Statistical analysis for SAR: The IC50 values for diarylheptanoids tested in NCI-H460. 
 
19     {19} *** *** *** *** / *** / *** *** *** *** *** / *** *** / *** ***   / / *** / / 
20     {20} *** *** *** *** * *** / / *** *** *** *** / *** * / / *** /   / *** / / 
21     {21} ** *** * *** ** ** / / *** *** *** *** * *** / ** / ** / /   *** * / 
22     {22} *** *** *** *** *** *** *** *** *** / * / *** *** *** *** *** *** *** *** ***   *** *** 
23     {23} *** *** *** *** / *** ** *** *** *** *** *** / *** *** / *** *** / / * ***   / 
24     {24} *** *** *** *** / *** / * *** *** *** *** / *** ** / / *** / / / *** /   
